"The U.S. Food and Drug Administration will complete its phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. This effort is to comply with an international treaty to protect the ozone layer by phasing "...
- Patient Information:
Details with Side Effects
There is no clinical syndrome associated with an overdosage of cromolyn sodium. In several animal species acute toxicity with cromolyn sodium occurs only with very high exposure levels. No deaths occurred at the highest oral doses tested in mice, 8,000 mg/kg (approximately 5,100 and 2,700 times the maximum recommended daily inhalation doses in adults and children, respectively, on a mg/m2 basis) or in rats, 8,000 mg/kg (approximately 10,000 and 5,400 times the maximum recommended daily inhalation doses in adults and children, respectively, on a mg/m2 basis).
Intal Inhaler (cromolyn sodium inhalation aerosol) is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium or other ingredients in this preparation.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Intal Inhaler Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.